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A systematic literature review was undertaken to synthesise the evidence that assessed the effectiveness and 30 cost-effectiveness of the presence of ward-based pharmacists for patients with a suspected or confirmed acute 31 medical emergency. It was undertaken in accordance with the standard methods for reviewing the clinical and 32 economic evidence specified in the NICE guidelines development manual. 11 No ethics approval was required for 33 this work.
34
Protocol development
35
The protocol for reviewing the effectiveness evidence was developed and approved by the guideline 36 development group (GDG), a team of experts consisting of 19 health care professionals including acute care 37 clinicians and a pharmacist in addition to two lay members and a technical team. The protocol specified the 38 inclusion and exclusion criteria (including the population, interventions and comparators, outcomes and study 39 design). These are briefly outlined below (Box 1).
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The protocol for reviewing the economic evidence was aligned with this in terms of the population, 41 interventions and comparators. Full economic evaluations (studies comparing costs and health consequences of 42 alternative courses of action which include cost-utility, cost-effectiveness, cost-benefit and cost-consequences 43 analyses) and comparative costing studies that addressed the review question in the relevant population were 44 considered potentially includable as health economic evidence.
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Exclusion criteria for the economic review included the following: 3-Studies from non-OECD countries or the USA were also excluded, on the basis that the applicability of 51 such studies to the present UK NHS context is likely to be too low for them to be helpful for decision- The population of interest was defined as adults and young people (16 years and over) admitted to hospital with a suspected or confirmed acute medical emergency (AME).
Interventions and comparators
The intervention was defined as "presence of medical ward-based pharmacists" and the comparator as "No ward-based pharmacists". The intervention was further stratified as either for less than 7 days a week or for 7 days a week.
Outcomes
-Mortality during the study period, -Avoidable adverse events during the study period, -Quality of life during the study period, -Patient and/or carer satisfaction during the study period, -Length of stay in hospital during the study period, -Readmissions within 30 days, future admissions to hospital (over 30 days), -Discharges during the study period, -Prescribing errors during the study period, -Missed medications during the study period, -Medicines reconciliation during the study period, -Staff satisfaction during the study period.
Inclusion and exclusion criteria
The key population inclusion criterion was:
• Adults (18 years and over) and young people (16-17 years) who seek, or are referred for, emergency NHS care for a suspected or confirmed acute medical emergency.
The key population exclusion criteria were:
• Continuous outcomes were analysed using an inverse variance method for pooling weighted mean differences.
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These outcomes included: quality of life, length of stay in hospital (LOS), patient and/or carer satisfaction.
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Where the studies within a single meta-analysis had different scales of measurement, standardised mean 87 differences were used (providing all studies reported either change from baseline or final values rather than a 88 mixture of both); each different measure in each study was 'normalised' to the standard deviation value pooled 89 between the intervention and comparator groups in that same study.
90
Statistical heterogeneity was assessed by considering the chi-squared test for significance at p<0.1 or an I-91 squared (I 2 ) inconsistency statistic (with an I-squared value of more than 50% indicating significant 92 heterogeneity) as well as the distribution of effects. Where significant heterogeneity was present, predefined 93 subgrouping of studies was carried out as per the protocols. 
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RESULTS
120
The search for RCTs retrieved 3196 records. Of these, 20 papers reporting on 18 RCTs were included in the 121 review. 14-33 A list of the excluded studies with reasons for exclusion are presented in Appendix 4 in the 
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The studies were split into 3 strata: regular ward-based pharmacist input (where the ward-based pharmacist 126 provided interventions throughout the patient stay on the ward, which included both admission and discharge 127 services), pharmacist input at admission, and pharmacist input at discharge. The interventions and comparators 128 were often not well defined and there was variation across the studies in their composition.
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The characteristics of the included RCTs and economic studies are summarised in Tables 1 and 2, Inclusion -admitted to the internal medicine service and remained in the same patient care unit until discharge.
Exclusion -none given.
Quasi-RCT
Pharmacist present on the ward. Duties included taking part in the rounding team, documenting medication history, and discharge counselling.
Standard care from 1 pharmacist (implication in paper that this is not wardbased).
Avoidable adverse drug events until discharge.
Length of stay inhospital (reported as mean difference).
Re-admission (unclear follow-up time, reported as percentage reduction).
Shen 2011 Patient and/or carer satisfaction.
Ward-based pharmacist input at admission
Aag 2014 14 
Norway
Consecutively admitted patients (n=201) to the Cardiology study ward at a University hospital.
Inclusion -aged 18 and over. arrival and discharge or transfer to a hospital ward).
Lisby 2010 25 Denmark Consecutively admitted patients (n=100) to acute internal medicine study ward within 1 regional hospital.
Inclusion -patients were 70 years or older.
RCT Pharmacist admission review.
Senior physician admission review.
Self-experienced quality of health at 3 months.
Length of stay in hospital. 
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Five economic evaluations were included in this stratum. 17 21 35-37 These were conducted in Belgium (n=3),
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Netherland (n=1) and the UK (n=1). Three studies reported that the ward-based pharmacist input was dominant 21 (more effective and less costly) compared to usual care. One cost-utility analysis (CUA) showed that the wardbased pharmacist intervention was cost-effective with an ICER of £632 per QALY-gained. One study showed 23 that regular ward-based pharmacist input was less effective and less costly, with no clear conclusion regarding 24 cost effectiveness given the absence of a cost-effectiveness threshold for the reported outcomes. All five studies 25 were assessed as partially applicable with potentially serious limitations. The results are summarised in Table   26 5.4, Appendix 5 and the quality assessment rationale in Appendix 7 in the Supplementary Material. 
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One comparative cost analysis (CCA) conducted in the UK showed that pharmacist input at admission was cost 43 saving compared to usual care (mean saving of £142 per patient). 34 The analysis was assessed as partially 44 applicable with potentially serious limitations. The results are summarised in Table 5 .4, Appendix 5 and the 45 quality assessment rationale in Appendix 7 in the Supplementary Material.
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Ward-based pharmacist input at discharge Four RCTs (n=770) evaluated provision of ward-based pharmacists' input at discharge. 15 16 18 27 The pharmacists 48 in the intervention arm in these studies were involved only at the discharge stage, for example preparing 49 patients' medications and providing counselling before discharge. The evidence suggested a benefit in terms of 50 reduced prescription errors (RR 0.57 (95% CI: 0.37 to 0.88), 1 study, low quality), reduced readmissions up to 51 22 days post discharge (RR 0.36 (95% CI: 0.14 to 0.91), 1 study, very low quality) and drug therapy 52 inconsistencies and omissions at discharge (RR 0.06 (95% CI: 0.01 to 0.44), 1 study, moderate quality). There
53
was no evidence of effect on quality of life (EQ-5D VAS: 2.8 (95% CI: -1.83 to 7.43), EQ-5D index: 0.05 54 higher (95% CI: -0.05 to 0.15), 1 study, very low to low quality). The results are summarised in the clinical 55 evidence profile in Appendix 5, 
